首页 > 最新文献

JCO Global Oncology最新文献

英文 中文
Erratum: Effect of Hospital Teaching Status on Mortality and In-Hospital Outcomes in Patients Hospitalized With Acute Leukemia: A National Study. 勘误:医院教学状况对急性白血病住院患者死亡率和住院结果的影响:一项全国性研究。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO-24-00380
{"title":"Erratum: Effect of Hospital Teaching Status on Mortality and In-Hospital Outcomes in Patients Hospitalized With Acute Leukemia: A National Study.","authors":"","doi":"10.1200/GO-24-00380","DOIUrl":"https://doi.org/10.1200/GO-24-00380","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer Care Disparities: Overcoming Barriers to Cancer Control in Low- and Middle-Income Countries. 癌症护理差异:克服中低收入国家的癌症控制障碍。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO.23.00439
Oluwaseun Adebayo Bamodu, Chen-Chih Chung

The rising global burden of cancer disproportionately affects low- and middle-income countries (LMICs), which account for over half of new patients and cancer deaths worldwide. However, LMIC health systems face profound challenges in implementing comprehensive cancer control programs because of limited health care resources and infrastructure. This analytical review explores contemporary evidence on barriers undermining cancer control efforts in resource-constrained LMIC settings. We conducted a comprehensive literature review of peer-reviewed evidence on cancer control challenges and solutions tailored to resource-limited settings. We provide a conceptual framework categorizing these barriers across the cancer care continuum, from raising public awareness to palliative care. We also appraise evidence-based strategies proposed to overcome identified obstacles to cancer control in the published literature, including task-shifting to nonspecialist health workers, strategic prioritization of high-impact interventions, regional collaborations, patient navigation systems, and novel financing mechanisms. Developing strong primary care delivery platforms integrated with specialized oncology care, alongside flexible and resilient health system models tailored to local contexts, will be critical to curb the rising tide of cancer in resource-limited settings. Urgent global commitments and investments are needed to dismantle barriers and expand access to prevention, early detection, diagnosis, treatment, and palliation services for all patients with cancer residing in LMICs as an ethical imperative. The review elucidates priority areas for policy actions, health systems strengthening, and future research to guide international efforts toward more equitable cancer control globally.

全球癌症负担日益加重,对中低收入国家的影响尤为严重,这些国家的癌症新增患者和死亡人数占全球的一半以上。然而,由于医疗资源和基础设施有限,中低收入国家的医疗系统在实施全面癌症控制计划方面面临着巨大挑战。这篇分析性综述探讨了在资源有限的低收入与中等收入国家环境中阻碍癌症控制工作的当代证据。我们对同行评审过的有关癌症控制挑战和针对资源有限环境的解决方案的证据进行了全面的文献综述。我们提供了一个概念框架,从提高公众意识到姑息治疗,对癌症治疗过程中的这些障碍进行了分类。我们还对已发表文献中为克服癌症控制障碍而提出的循证策略进行了评估,这些策略包括将任务转移给非专业卫生工作者、高影响力干预措施的战略优先次序、区域合作、患者导航系统以及新型融资机制。发展与肿瘤专科护理相结合的强大的初级保健服务平台,同时根据当地情况建立灵活而有弹性的卫生系统模式,对于遏制资源有限环境中不断上升的癌症浪潮至关重要。全球亟需做出承诺并进行投资,以消除障碍并扩大居住在低收入和中等收入国家的所有癌症患者获得预防、早期检测、诊断、治疗和姑息治疗服务的机会,这也是一项道德义务。本综述阐明了政策行动、卫生系统强化和未来研究的优先领域,以指导国际社会努力在全球范围内实现更公平的癌症控制。
{"title":"Cancer Care Disparities: Overcoming Barriers to Cancer Control in Low- and Middle-Income Countries.","authors":"Oluwaseun Adebayo Bamodu, Chen-Chih Chung","doi":"10.1200/GO.23.00439","DOIUrl":"https://doi.org/10.1200/GO.23.00439","url":null,"abstract":"<p><p>The rising global burden of cancer disproportionately affects low- and middle-income countries (LMICs), which account for over half of new patients and cancer deaths worldwide. However, LMIC health systems face profound challenges in implementing comprehensive cancer control programs because of limited health care resources and infrastructure. This analytical review explores contemporary evidence on barriers undermining cancer control efforts in resource-constrained LMIC settings. We conducted a comprehensive literature review of peer-reviewed evidence on cancer control challenges and solutions tailored to resource-limited settings. We provide a conceptual framework categorizing these barriers across the cancer care continuum, from raising public awareness to palliative care. We also appraise evidence-based strategies proposed to overcome identified obstacles to cancer control in the published literature, including task-shifting to nonspecialist health workers, strategic prioritization of high-impact interventions, regional collaborations, patient navigation systems, and novel financing mechanisms. Developing strong primary care delivery platforms integrated with specialized oncology care, alongside flexible and resilient health system models tailored to local contexts, will be critical to curb the rising tide of cancer in resource-limited settings. Urgent global commitments and investments are needed to dismantle barriers and expand access to prevention, early detection, diagnosis, treatment, and palliation services for all patients with cancer residing in LMICs as an ethical imperative. The review elucidates priority areas for policy actions, health systems strengthening, and future research to guide international efforts toward more equitable cancer control globally.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Factors Affecting Cancer Diagnosis and Treatment Delays in Ukraine. 勘误:影响乌克兰癌症诊断和治疗延误的因素。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO-24-00376
{"title":"Erratum: Factors Affecting Cancer Diagnosis and Treatment Delays in Ukraine.","authors":"","doi":"10.1200/GO-24-00376","DOIUrl":"https://doi.org/10.1200/GO-24-00376","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142086112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: A Feasibility Study of a Behavioral Intervention to Increase Uptake of Human Papillomavirus (HPV) Vaccination in Envigado, Colombia. 勘误:在哥伦比亚恩维加多开展行为干预以提高人类乳头瘤病毒 (HPV) 疫苗接种率的可行性研究。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO-24-00385
{"title":"Erratum: A Feasibility Study of a Behavioral Intervention to Increase Uptake of Human Papillomavirus (HPV) Vaccination in Envigado, Colombia.","authors":"","doi":"10.1200/GO-24-00385","DOIUrl":"https://doi.org/10.1200/GO-24-00385","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Deciphering the Nuclear Role of Heme Oxygenase-1 in Prostate Cancer: Transcriptional Reprogramming and Neuroendocrine Differentiation. 勘误:解密血红素加氧酶-1 在前列腺癌中的核作用:转录重编程与神经内分泌分化
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO-24-00382
{"title":"Erratum: Deciphering the Nuclear Role of Heme Oxygenase-1 in Prostate Cancer: Transcriptional Reprogramming and Neuroendocrine Differentiation.","authors":"","doi":"10.1200/GO-24-00382","DOIUrl":"https://doi.org/10.1200/GO-24-00382","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: If I Have the Courage…I Prefer to See a Doctor: A Qualitative Exploration of Ethiopian Women's Hesitancy to Screen for Cervical Cancer Using HPV Self-Sampling. 勘误:如果我有勇气......我宁愿去看医生:埃塞俄比亚妇女不愿使用 HPV 自我采样筛查宫颈癌的定性研究。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO-24-00375
{"title":"Erratum: If I Have the Courage…I Prefer to See a Doctor: A Qualitative Exploration of Ethiopian Women's Hesitancy to Screen for Cervical Cancer Using HPV Self-Sampling.","authors":"","doi":"10.1200/GO-24-00375","DOIUrl":"https://doi.org/10.1200/GO-24-00375","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142086113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Imparting Knowledge to Others: A Qualitative Study Exploring How Ethiopian Women Prefer to Receive Cervical Cancer Education. 勘误:向他人传授知识:埃塞俄比亚妇女如何选择接受宫颈癌教育的定性研究。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO-24-00374
{"title":"Erratum: Imparting Knowledge to Others: A Qualitative Study Exploring How Ethiopian Women Prefer to Receive Cervical Cancer Education.","authors":"","doi":"10.1200/GO-24-00374","DOIUrl":"https://doi.org/10.1200/GO-24-00374","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142086114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Impact of Project ECHO in Children With Cancer in Western Kenya: A Case Series. ECHO 项目对肯尼亚西部癌症儿童的临床影响:病例系列。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO-24-00279
Gilbert Olbara, Festus Njuguna, Mary Ann Etling, Sandra Langat, Martha Kipng'etich, Charles N Nessle, Gertjan J L Kaspers, Terry A Vik, Tyler S Severance
{"title":"Clinical Impact of Project ECHO in Children With Cancer in Western Kenya: A Case Series.","authors":"Gilbert Olbara, Festus Njuguna, Mary Ann Etling, Sandra Langat, Martha Kipng'etich, Charles N Nessle, Gertjan J L Kaspers, Terry A Vik, Tyler S Severance","doi":"10.1200/GO-24-00279","DOIUrl":"10.1200/GO-24-00279","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in Presentation, Management, and Survival of Women With Breast Cancer in a Multiethnic, Middle-Income Asian Setting. 在一个多民族、中等收入的亚洲环境中,乳腺癌女性患者的发病、管理和生存趋势。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO.24.00054
Sharminii Jaya-Prakason, Yek-Ching Kong, Cheng-Har Yip, Mee-Hoong See, Nur Aishah Taib, Nur Fadhlina Abdul Satar, Suniza Jamaris, Li Ying Teoh, Rose Irnawaty Ibrahim, Nirmala Bhoo-Pathy

Purpose: Granular data on breast cancer (BC) are pertinent for surveillance, planning, and monitoring of cancer care delivery. We determined the trends in clinical presentation, management, and survival of women with BC in a multiethnic middle-income Asian setting over 15 years.

Methods: Data of 7,478 Malaysian women newly diagnosed with invasive BC between 2005 and 2019 from three hospital-based cancer registries were included. Trends in demographic, tumor, and treatment characteristics were compared across period 1 (P1): 2005-2009, period 2 (P2): 2010-2014, and period 3 (P3): 2015-2019. Overall survival and net survival were determined.

Results: More women in P3 than P1 were older than 60 years at diagnosis. Only a marginal increase in proportion of women with stage I disease was observed (23.7% v 27.2% in P1 and P3, respectively, P = .004). Nonetheless, patients were increasingly presenting with smaller tumors, fewer axillary node involvement, well-differentiated tumors, and hormone receptor expression in recent times. Proportion of women with human epidermal growth factor receptor 2 (HER2)-overexpressed tumors significantly decreased. Among indicated patients, receipt of anticancer therapies was somewhat similar over the calendar periods, except for neoadjuvant chemotherapy and anti-HER2 therapy, where increases in administration were noted. Significant improvements in survival were observed over the 15 years, particularly for HER2-overexpressed BCs.

Conclusion: Although the improvements in BC survival that we have observed validate ongoing cancer control efforts and treatment advances, study findings suggest that more could be done for earlier detection and improved access to effective therapies in our settings.

目的:有关乳腺癌(BC)的详细数据对癌症护理服务的监测、规划和监控至关重要。我们确定了一个多民族中等收入亚洲环境中患乳腺癌妇女 15 年来的临床表现、管理和生存趋势:方法:纳入了 2005 年至 2019 年间新诊断为浸润性 BC 的 7478 名马来西亚妇女的数据,这些数据来自三个以医院为基础的癌症登记处。比较了第 1 期(P1)、第 2 期(P2)、第 3 期(P4)和第 4 期(P5)的人口统计、肿瘤和治疗特征趋势:2005-2009年,第二阶段(P2):2010-2014年,以及时期3(P3):2015-2019.确定了总生存率和净生存率:与 P1 相比,P3 中确诊时年龄超过 60 岁的女性人数更多。I期女性比例仅略有增加(P1和P3分别为23.7%和27.2%,P = .004)。尽管如此,近来越来越多的患者表现为肿瘤较小、腋窝结节受累较少、肿瘤分化良好以及激素受体表达。人类表皮生长因子受体 2(HER2)表达肿瘤的女性比例明显下降。除了新辅助化疗和抗 HER2 治疗的用药量有所增加外,其他历时段内已确诊患者接受抗癌治疗的情况大致相同。15年间,患者的生存率显著提高,尤其是HER2暴露的BC患者:尽管我们观察到的 BC 存活率的提高证明了癌症控制工作和治疗方法的不断进步,但研究结果表明,在我们的环境中,还需要做更多的工作,以便更早地发现癌症,并更好地获得有效的治疗方法。
{"title":"Trends in Presentation, Management, and Survival of Women With Breast Cancer in a Multiethnic, Middle-Income Asian Setting.","authors":"Sharminii Jaya-Prakason, Yek-Ching Kong, Cheng-Har Yip, Mee-Hoong See, Nur Aishah Taib, Nur Fadhlina Abdul Satar, Suniza Jamaris, Li Ying Teoh, Rose Irnawaty Ibrahim, Nirmala Bhoo-Pathy","doi":"10.1200/GO.24.00054","DOIUrl":"10.1200/GO.24.00054","url":null,"abstract":"<p><strong>Purpose: </strong>Granular data on breast cancer (BC) are pertinent for surveillance, planning, and monitoring of cancer care delivery. We determined the trends in clinical presentation, management, and survival of women with BC in a multiethnic middle-income Asian setting over 15 years.</p><p><strong>Methods: </strong>Data of 7,478 Malaysian women newly diagnosed with invasive BC between 2005 and 2019 from three hospital-based cancer registries were included. Trends in demographic, tumor, and treatment characteristics were compared across period 1 (P1): 2005-2009, period 2 (P2): 2010-2014, and period 3 (P3): 2015-2019. Overall survival and net survival were determined.</p><p><strong>Results: </strong>More women in P3 than P1 were older than 60 years at diagnosis. Only a marginal increase in proportion of women with stage I disease was observed (23.7% <i>v</i> 27.2% in P1 and P3, respectively, <i>P</i> = .004). Nonetheless, patients were increasingly presenting with smaller tumors, fewer axillary node involvement, well-differentiated tumors, and hormone receptor expression in recent times. Proportion of women with human epidermal growth factor receptor 2 (HER2)-overexpressed tumors significantly decreased. Among indicated patients, receipt of anticancer therapies was somewhat similar over the calendar periods, except for neoadjuvant chemotherapy and anti-HER2 therapy, where increases in administration were noted. Significant improvements in survival were observed over the 15 years, particularly for HER2-overexpressed BCs.</p><p><strong>Conclusion: </strong>Although the improvements in BC survival that we have observed validate ongoing cancer control efforts and treatment advances, study findings suggest that more could be done for earlier detection and improved access to effective therapies in our settings.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experiences and Satisfaction With Telehealth During the COVID-19 Pandemic: The Perspectives of Patients With Cancer in Australia. 在 COVID-19 大流行期间对远程保健的体验和满意度:澳大利亚癌症患者的观点。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/GO.24.00081
Arnav Nanda, Lyn Ley Lam, Jodi Lynch, Hussein Soudy

Purpose: There has been a significant rise in telehealth consultations across Australia since COVID-19 was declared a worldwide pandemic. We aimed to obtain patient feedback on telehealth, identify key strengths and weaknesses, and assess the feasibility of telehealth beyond the pandemic.

Methods: A survey was developed to obtain patient feedback on telehealth. Patients attending medical oncology clinics at St George Hospital and Sutherland Hospital from April 1, 2020, to May 31, 2020, were identified. Patients who were reviewed via phone or videoconference were included in this study. Eligible patients were texted or emailed a survey link within a week of their telehealth consultation. Surveys were anonymous and completion of the survey implied informed consent. Patients who did not have a mobile number or e-mail were excluded from this study.

Results: One thousand fifty-nine patients were reviewed during the study period, of whom 644 (60%) were reviewed via telehealth. The survey response rate was 36.3% (230 patients responded of 634 surveys sent). Ten telehealth patients did not have a mobile number or email and were excluded. Sixty-seven percent of telehealth consults were for active surveillance, 31% for prechemotherapy/treatment reviews, 1.6% for best supportive care, and 0.5% for new consults. Seventy percent of patients were satisfied that their medical needs were met via telehealth. Ninety percent wanted another telehealth consult, and 73% wanted telehealth to continue post resolution of the pandemic. Minimizing risk of exposure to COVID-19 and patient convenience were identified as key strengths of telehealth while absence of physical examination was the main disadvantage.

Conclusion: Majority of the patients surveyed were satisfied that telehealth safely met their medical needs. There is a considerable demand for telehealth to continue beyond the pandemic.

目的:自从 COVID-19 被宣布为世界性流行病以来,澳大利亚各地的远程医疗咨询量显著增加。我们的目的是获取患者对远程医疗的反馈意见,确定关键的优势和劣势,并评估大流行过后远程医疗的可行性:方法:我们制定了一项调查,以获取患者对远程医疗的反馈意见。调查对象为 2020 年 4 月 1 日至 2020 年 5 月 31 日期间在圣乔治医院和萨瑟兰医院肿瘤内科门诊就诊的患者。通过电话或视频会议接受审查的患者被纳入本研究。符合条件的患者会在接受远程医疗会诊后一周内收到短信或电子邮件中的调查链接。调查是匿名的,完成调查即表示知情同意。没有手机号码或电子邮件的患者被排除在本研究之外:研究期间对 159 名患者进行了复查,其中 644 人(60%)通过远程医疗进行了复查。调查回复率为 36.3%(在发出的 634 份调查问卷中,有 230 名患者做出了回复)。有 10 名远程医疗患者没有手机号码或电子邮件,因此被排除在外。67%的远程医疗咨询用于主动监测,31%用于化疗前/治疗复查,1.6%用于最佳支持治疗,0.5%用于新咨询。70%的患者对通过远程医疗满足其医疗需求表示满意。90%的患者希望再次接受远程医疗咨询,73%的患者希望在大流行结束后继续使用远程医疗。最大限度地降低接触 COVID-19 的风险和为患者提供方便被认为是远程医疗的主要优势,而无法进行体检则是其主要劣势:大多数接受调查的患者对远程保健安全地满足了他们的医疗需求表示满意。大流行过后,远程医疗仍有很大的发展空间。
{"title":"Experiences and Satisfaction With Telehealth During the COVID-19 Pandemic: The Perspectives of Patients With Cancer in Australia.","authors":"Arnav Nanda, Lyn Ley Lam, Jodi Lynch, Hussein Soudy","doi":"10.1200/GO.24.00081","DOIUrl":"https://doi.org/10.1200/GO.24.00081","url":null,"abstract":"<p><strong>Purpose: </strong>There has been a significant rise in telehealth consultations across Australia since COVID-19 was declared a worldwide pandemic. We aimed to obtain patient feedback on telehealth, identify key strengths and weaknesses, and assess the feasibility of telehealth beyond the pandemic.</p><p><strong>Methods: </strong>A survey was developed to obtain patient feedback on telehealth. Patients attending medical oncology clinics at St George Hospital and Sutherland Hospital from April 1, 2020, to May 31, 2020, were identified. Patients who were reviewed via phone or videoconference were included in this study. Eligible patients were texted or emailed a survey link within a week of their telehealth consultation. Surveys were anonymous and completion of the survey implied informed consent. Patients who did not have a mobile number or e-mail were excluded from this study.</p><p><strong>Results: </strong>One thousand fifty-nine patients were reviewed during the study period, of whom 644 (60%) were reviewed via telehealth. The survey response rate was 36.3% (230 patients responded of 634 surveys sent). Ten telehealth patients did not have a mobile number or email and were excluded. Sixty-seven percent of telehealth consults were for active surveillance, 31% for prechemotherapy/treatment reviews, 1.6% for best supportive care, and 0.5% for new consults. Seventy percent of patients were satisfied that their medical needs were met via telehealth. Ninety percent wanted another telehealth consult, and 73% wanted telehealth to continue post resolution of the pandemic. Minimizing risk of exposure to COVID-19 and patient convenience were identified as key strengths of telehealth while absence of physical examination was the main disadvantage.</p><p><strong>Conclusion: </strong>Majority of the patients surveyed were satisfied that telehealth safely met their medical needs. There is a considerable demand for telehealth to continue beyond the pandemic.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JCO Global Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1